Lucid Diagnostics Inc.
NASDAQ:LUCDMedical - Devices
+$0.04 today
- Market cap
- $79.38M
- Beta
- 1.08
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.44
Volume 2.70M
Average 0.84M
LUCD Net Income
Bottom-line profit after all expenses, interest, and taxes.
Lucid Diagnostics Inc.NASDAQ: LUCD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$13.91M, compared with -$26.91M a year earlier. Trailing-twelve-month net income was -$45.01M.
Context
- Net income amounted to 1232.7% of revenue in FY2025, up 185.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$28.82M (+50.3%) for the fiscal year ending Dec 2026, a step up from the -27.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.91M+14.5% QoQ
- Last fiscal yearDec 2025
- -$58.01M-27.4% YoY
- LTMMar 2026
- -$45.01M+27.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.3% | -143.8% | -192.1 pp |
| 1 year | -27.4% | +50.3% | +77.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (58.01M) USD
- Year-over-year change
- -27.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (58.01M) | -27.4% |
| FY2024 | 2024-12-31 | (45.53M) | +13.6% |
| FY2023 | 2023-12-31 | (52.67M) | +6.2% |
| FY2022 | 2022-12-31 | (56.17M) | -100.1% |
| FY2021 | 2021-12-31 | (28.08M) | — |
Net Income vs competitors
How LUCD compares with its peers on the latest reported figures
- LUCD's LTM Mar 2026 net income of -$45.01M is the 2nd highest of the 10 companies compared; the peer median is -$70.49M.
- Its year-over-year change of +27.2% is the 2nd highest of 10, against a peer median of -16.5%.
- Net income amounts to 876.7% of revenue for LUCD, versus a peer median of 468.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$9.17M | +54.2% | — | 16.4% | |
| LTM Mar 2026 | -$45.01M | +27.2% | — | 876.7% | |
| LTM Mar 2026 | -$45.34M | +20.5% | — | 62.7% | |
| LTM Mar 2026 | -$46.04M | -260.1% | — | 43.0% | |
| LTM Mar 2026 | -$50.14M | -11.8% | — | 145.8% | |
| LTM Mar 2026 | -$70.49M | +17.9% | — | 468.7% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -$95.3M | -16.5% | — | 5148.8% |
IRDOpus Genetics, Inc. | LTM Mar 2026 | -$106.93M | -82.4% | — | 892.4% |
| LTM Mar 2026 | -$370.67M | -5705.3% | — | 93391.3% | |
| LTM Mar 2026 | -$419.68M | -463.2% | — | 1239.4% | |
| Peer median (excluding LUCD) | -$70.49M | -16.5% | — | 468.7% | |
Competitors are the stored peer set for LUCD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 500K | 377K | 2.43M | 4.35M | 4.71M |
| Cost of Revenue | 585K | 3.61M | 8.48M | 8.27M | 7.54M |
| Gross Profit | (85K) | (3.24M) | (6.05M) | (3.92M) | (2.84M) |
| Gross Margin | -17.0% | -858.6% | -249.2% | -90.2% | -60.3% |
| Research & Development | 9.3M | 11.47M | 7.25M | 5.99M | 5.68B |
| Selling, General & Admin | 18.04M | 39.82M | 35.66M | 36.62B | 41.58B |
| Operating Expenses | 27.33M | 52.93M | 42.43M | 42.13M | 46.8M |
| Depreciation & Amortization | 4K | 1.94M | 2.5M | 1.17M | 872K |
| EBITDA | (27.42M) | (54.23M) | (49.75M) | (44.34M) | (57.12M) |
| EBITDA Margin | -5483.0% | -14383.8% | -2049.1% | -1020.2% | -1213.7% |
| Operating Income | (27.42M) | (56.17M) | (48.48M) | (46.05M) | (49.64M) |
| Operating Margin | -5483.8% | -14899.5% | -1996.8% | -1059.6% | -1054.8% |
| Interest Income | 0 | 88K | 424K | 322K | 386K |
| Interest Expense | 659K | 8K | 416K | 26K | 22K |
| Other Income / Expenses | (659K) | 0 | (4.18M) | 523K | (8.37M) |
| Income Before Tax | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Pre-Tax Margin | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.08M) | (56.17M) | (52.67M) | (45.53M) | (58.01M) |
| Net Margin | -5615.6% | -14899.5% | -2169.1% | -1047.6% | -1232.7% |
| EPS (Basic) | (0.78) | (1.55) | (1.26) | (1.05) | (0.69) |
| EPS (Diluted) | (0.78) | (1.55) | (1.26) | (1.05) | (0.69) |
| Weighted Avg Shares | 36.06M | 36.17M | 41.76M | 50.52M | 101.95M |
| Weighted Avg Shares (Diluted) | 36.06M | 36.17M | 41.76M | 50.52M | 101.95M |
Lucid Diagnostics Inc.
NASDAQ:LUCD
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.